Skip to main content
OpenTrials

Clinical trial condition

Leukemia, Lymphocytic, Chronic, B-Cell

Explore clinical trials studying Leukemia, Lymphocytic, Chronic, B-Cell. Study availability and eligibility vary by location and protocol.

1,434 public trials 165 recruiting studies
Refine in advanced search Browse all conditions

Leukemia, Lymphocytic, Chronic, B-Cell trial results

Completed

Assessment of Financial Difficulty in Participants with Chronic Lymphocytic Leukemia and Multiple Myeloma

NCT03870633

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Chronic Disease, +23 more
Locations
  • Alaska Oncology and Hematology LLC Anchorage, Alaska, United States
  • Anchorage Oncology Centre Anchorage, Alaska, United States
  • Katmai Oncology Group Anchorage, Alaska, United States
  • Providence Alaska Medical Center Anchorage, Alaska, United States
View all 116 locations
View Trial Details
Completed

Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT)

NCT04716075

Conditions
Adverse Event, Bronchial Diseases, Bronchiolitis, +33 more
Locations
  • Szpital Kliniczny Przemienienia Pańskiego, Oddział Hematologii i Transplantacji Szpiku Poznan, Greater Poland Voivodeship, Poland
  • Instytut Hematologii i Transfuzjologii Warsaw, Masovian Voivodeship, Poland
  • Narodowy Intytut Onkologii im. M. Skłodowskiej-Curie Oddział w Krakowie, Pododdział Leczenia Nowotworów Układu Chłonnego Krakow, Małopolska, Poland
  • Klinika Transplantacji Szpiku i Onkohematologii; Centrum Onkologii Instytut im. M.Sklodowskiej-Curie, Oddz. w Gliwicach Gliwice, Silesian Voivodeship, Poland
View Trial Details
Completed

Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation

NCT02950051

Conditions
Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +14 more
Locations
  • Medizinische Universitaet Wien Vienna, Austria
  • Hanusch Hospital Vienna, Austria
  • Wilhelminenspital Vienna, Austria
  • ZNA Stuivenberg Antwerp, Belgium
View all 161 locations
View Trial Details
Completed

Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)

NCT02910583

Conditions
Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +15 more
Locations
  • City of Hope /ID# 1142-0047 Duarte, California, United States
  • Moores Cancer Center at UC San Diego /ID# 1142-0241 La Jolla, California, United States
  • UC Irvine Medical Center - Chao Family Comprehensive Cancer Center /ID# 1142-0008 Orange, California, United States
  • Norton Cancer Center /ID# 1142-0071 Louisville, Kentucky, United States
View all 46 locations
View Trial Details
Completed

Acalabrutinib Study in Indian Patients With Chronic Lymphocytic Leukaemia & Relapsed and Refractory Mantle Cell Lymphoma

NCT04930536

Conditions
Chronic Disease, Chronic Lymphocytic Leukemia and Relapsed and Refractory Mantle Cell Lymphoma, Disease Attributes, +18 more
Locations
  • Research Site Ahmedabad, India
  • Research Site Bangalore, India
  • Research Site Bangalore, India
  • Research Site Bengaluru, India
View all 15 locations
View Trial Details
Completed

A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL

NCT02268851

Conditions
Chronic Disease, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Disease Attributes, +18 more
Locations
  • Pacific Cancer Care Monterey, California, United States
  • St. Francis Hospital and Cancer Center Hartford, Connecticut, United States
  • Eastern Maine Medical Center/ Northern Light Cancer Care Brewer, Maine, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
View Trial Details

Related conditions